Ghrelin, a gut-brain peptide, is best known for its role in the stimulation of feeding and growth hormone release. In the brain, orexin, neuropeptide Y (NPY) and ghrelin are parts of a food intake regulatory circuit. Orexin and NPY are also implicated in maintaining wakefulness. Previous experiments in our laboratory revealed that intracerebroventricular injections of ghrelin induce wakefulness in rats. To further elucidate the possible role of ghrelin in the regulation of arousal we studied the effects of microinjections of ghrelin into hypothalamic sites, which are implicated in the regulation of feeding and sleep, such as the lateral hypothalamus (LH), medial preoptic area (MPA) and paraventricular nucleus (PVN) on sleep in rats. Sleep responses, motor activity and food intake after central administration of 0.04, 0.2, or 1 µg (12, 60 or 300 pmol) ghrelin, were recorded. Microinjections of ghrelin into the LH had strong wakefulness-promoting effects lasting for 2 hours. Wakefulness was also stimulated by ghrelin injection into the MPA and PVN; the effects were confined to the first hour after the injection. Ghrelin's NREMS-suppressive effect was accompanied by attenuation in the electroencephalographic (EEG) slow-wave activity and changes in the EEG power spectrum. Food consumption was significantly stimulated after microinjections of ghrelin into each hypothalamic site. Together, these results are consistent with the hypothesis that forebrain ghrelinergic mechanisms play a role in the regulation of vigilance, possibly through activating the components of the food intake and arousalpromoting network formed by orexin and NPY.
INTRODUCTION
Ghrelin is a 28-amino acid peptide produced by endocrine cells in the gastrointestinal system and by neurons in the central nervous system (21) . Circulating ghrelin is derived mainly from the stomach (1) . Plasma ghrelin levels inversely correlate with feeding; fasting increases, while food intake reduces, plasma ghrelin concentrations (7; 61) . In the brain, ghrelin is produced by arcuate nucleus (ARC) neurons and by a distinct hypothalamic neuronal population in the internuclear region (6). Ghrelin's actions are mediated by the growth hormone secretagogue receptor (GHS-R) (21) . GHS-R mRNA is widely distributed in the gastrointestinal tract, sensory vagus fibers and the brain. Those hypothalamic nuclei that are implicated in the regulation of feeding and/or sleep-wake activity, such as the lateral hypothalamus (LH), paraventricular nucleus (PVN), ARC, dorsomedial hypothalamic nucleus (DMH), anteroventral preoptic nucleus, anterior hypothalamic area, suprachiasmatic nucleus, anterolateral hypothalamic nucleus and the tuberomamillary nucleus (TMN), are relatively abundant in GHS-R (14; 31).
The most widely studied effects of ghrelin are its actions on feeding and its stimulation of growth hormone secretion. In addition, it promotes fat deposition, stimulates gastrointestinal motility, gastric secretion and the activity of the hypothalamo-pituitary axis (HPA-axis) (22) . Ghrelin induces anxiety-like behavior and affects memory (3) .
Systemic administration of ghrelin strongly stimulates feeding in rats (66) and enhances food intake and appetite (49; 64) and induces imagination of food (49) in humans. It is hypothesized that circulating ghrelin, acting as a classic hormone, stimulates eating, an Page 4 of 42 5 action linked to vagal afferents (8) and the ARC (22) . Further, ghrelin-producing neurons, together with orexin and neuropeptide Y (NPY) cells, are also part of a food intake-regulatory hypothalamic circuit (22) .
Our previous experiments revealed that intracerebroventricular (icv) administration of ghrelin suppresses non-rapid-eye-movement sleep (NREMS) and strongly stimulates wakefulness and eating when injected in the rest phase of rats (52) . We hypothesized that ghrelin, acting on central GHS-R, may stimulate a behavioral sequence, which includes increased feeding and increased time spent awake. These behavioral manifestations are characteristic of the first hour of the activity period in rats (dark onset syndrome). To characterize the possible hypothalamic sites which may mediate these actions, we studied the sleep and feeding responses to microinjections of three doses of ghrelin in rats. We report herein that ghrelin administration into the LH, medial preoptic area (MPA) and PVN of rats dose-dependently increases food intake and the amount of wakefulness and decreases sleep in the first hour after injection.
Page 5 of 42 
METHODS

Animals and surgical procedures.
Using ketamine (87 mg/kg) and xylazine (13 mg/kg) anesthesia, male Sprague-Dawley rats (275-325 g) were implanted with cortical electroencephalographic (EEG) electrodes and nuchal electromyographic (EMG) electrodes. Stereotaxic equipment was used to insert guide cannulae (Plastics One, 26 G) bilaterally into the LH (n = 8 per dose), MPA (n = 7 per dose) and unilaterally into the PVN (n = 6-8 per dose) of the hypothalamus.
The coordinates of the tip of the guide cannulae were: 2.1 mm posterior and 2 mm lateral to the bregma, and 7.8 mm ventral from the surface of the skull for LH; 0.4 mm posterior and 1.85 mm lateral to the bregma, and 7.8 mm ventral from the surface of the skull for MPA, and 1.80 mm posterior and 0.4 mm lateral to the bregma, and 7.5 mm ventral from the surface of the skull for PVN according to the rat brain atlas by Paxinos and Watson (39) . The guide cannulae into the MPA and PVN were inserted at a 10º angle from vertical. Substances were administered by a 31-gauge stainless steel injector placed in and projecting 0.5 mm beyond the tip of the cannulae. The position of the cannulae was verified by histology at the end of the experiment. After the surgeries, the animals were placed in individual sleep recording cages in sound-attenuated, temperature-regulated environmental chambers at 24 ± 1ºC ambient temperature on a 12:12 hours dark-light cycle (light on at 9:00 a.m.) for habituation to the experimental conditions for at least 7 days. During this adaptation period, the animals were connected to the recording cables and handled daily to habituate them to the microinjection procedure. Water and food were available ad libitum. Institutional guidelines for the care and use of research power density values in the delta range were averaged across the entire 23 h for each rat to obtain a reference value for that rat. Slow-wave activities for each hour on the baseline day and the test days were expressed as a percent of that reference value.
Experimental protocol.
The treatments were done 10-15 min prior to light onset. The injected volumes were 100 nl per injection site given over 1 min. After the injection, the injectors were left in Page 7 of 42 8 the guide for an additional minute. On the control day, the animals received 100 nl pyrogen-free isotonic NaCl; on the experimental day, they were injected with ghrelin [0.04 µg, 0.2 µg or1 µg/injection site, (12, 60 and 300 pmol, respectively) Bachem California Inc., Torrance, Ca] dissolved in isotonic NaCl (100 nl). The order of the control and experimental days was counterbalanced. Immediately after injection, the animals were returned to their home cages. Food and water were provided ad libitum during the entire recording period. A preweighed amount of chow was placed on a plastic tray at light onset; the pellet leftovers were collected and reweighed 1 hour later.
Sleep was continuously recorded for 23 h starting from the beginning of light onset.
Verification of cannula placement.
To verify the location of the microinjection cannulae, 0. 
Statistics.
Two-way analysis of variance (ANOVA) for repeated measures was performed on sleep and power spectra data (factors: treatment and time effect or treatment and frequency effect, respectively). For SWA analysis, those hours during which a rat did not have at 
RESULTS
The effects of lateral hypothalamic injection of ghrelin on sleep, EEG and food intake
( Figures 1, 2 and 7 ).
The lowest dose of ghrelin, 0.04 µg, did not have any significant effect on the amount of wakefulness, NREMS and REMS and did not affect the SWA of the EEG (Fig. 1 ).
Detailed analysis of the EEG power revealed a significant increase in the 6-8 Hz frequency range during wakefulness (ANOVA, treatment x frequency interaction: F(31,186) = 4.6, p < 0.05) (Fig 2. ). There was no significant change in the food intake of the rats in response to 0.04 µg ghrelin (Fig. 7) .
Administration of 0.2 µg ghrelin significantly increased the time spent in wakefulness and decreased the time in NREMS and REMS (ANOVA h 1-3, treatment effect for wake: F(1,7) = 16.2; p < 0.05; for NREMS: F(1,7) = 13.4, p < 0.05; for REMS: F(1,7) = 27.5, p < 0.05) (Fig. 1) . The effects on wake and NREMS were confined to the first two hours of the recording period, while REMS changes were significant in hours 2 and 3 (SNK test). There was a significant effect on EEG SWA in the first 3 hours as indicated by F(31,155) = 1.9, p < 0.05) (Fig. 2) . Injection of 0.2 µg ghrelin significantly increased the 1-hour food intake of the rats from a baseline of 0.65 ± 0.56 g/kg BW to 6.36 ± 1.16 g/kg BW after ghrelin treatment.
The effects of 1 µg ghrelin injection on sleep were similar to those of the middle dose ( Fig. 1) . Following ghrelin injection wakefulness significantly increased and NREMS decreased (ANOVA h 1-3, treatment effect for wake: F(1,7) = 8.5, p < 0.05; for NREMS: F(1,7) = 9.9, p < 0.05). Post hoc analysis showed significant changes in wake and NREMS in the first two hours after ghrelin treatment. EEG SWA was significantly attenuated in the first hour following ghrelin injection (ANOVA treatment x time interaction: F(2,36) = 3.9, p < 0.05). Detailed analysis of the EEG power showed a significant decrease in the 2.5-3 Hz range during NREMS (ANOVA treatment x frequency interaction: F(31,124) = 1.2, p < 0.05); during REMS, there was a significant increase in the 6.5-7 Hz and a decrease in the 8-8.5 Hz frequency ranges (ANOVA treatment x frequency interaction: F(31,155) = 2.4, p < 0.05) (Fig. 2) . One µg ghrelin significantly stimulated the 1-h food intake of the rats (0.25 ± 0.14 g/kg BW after control treatment vs. 7.02 ± 1.75 g/kg BW after ghrelin treatment) (Fig. 7) .
The effects of ghrelin injection into the medial preoptic area of the hypothalamus on
sleep, EEG and food intake ( Figures 3, 4 and 7) .
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The lowest dose of ghrelin, 0.04 µg, did not induce any statistically significant change in the time spent in wake, NREMS or REMS and did not alter the EEG SWA (Fig. 3) or food intake (Fig. 7) . There was a significant increase in the EEG power in the 7-9 Hz frequencies during wake (ANOVA treatment x time interaction: F(31,186) = 2.0, p < 0.05) and a significant decrease in the 1.5-3 Hz frequencies during NREMS (ANOVA treatment x time interaction: F(31,186) = 3.6, p < 0.05) (Fig. 4) .
The middle dose of ghrelin, 0.2 µg, induced a significant increase in time spent awake at the expense of both NREMS and REMS, as indicated by ANOVA (ANOVA h 1-3, treatment effect for wake: F(1,6) = 26.6; p < 0.05; for NREMS: F(1,6) = 12.9; p < 0.05; for REMS: F(1,6) = 15.9; p < 0.05). Post hoc analysis showed the effects to be confined to the first hour of the recording period. EEG SWA slightly but significantly increased beginning from the fourth hour (ANOVA h 4-23, treatment effect: F(1,6) = 9.9, p < 0.05) (Fig. 3) . EEG power during wake was increased in the 5-5. (Fig. 4) . Injection of 0.2 µg ghrelin was followed by a significant increase (5.01 ± 0.53 g/kg BW vs. 0.45 ± 0.23 g/kg BW after saline injection) in feeding (Fig. 7) . (Fig. 3) . The EEG power during wake and sleep was also affected (Fig. 4) . One µg ghrelin induced a decrease in EEG power in the 1-3.5 Hz frequency range during wake (ANOVA treatment effect: F(1,6) = 18.1, p < 0.05), in the 0.5-7 Hz frequencies during NREMS (ANOVA treatment effect: F(1,6) = 15.2, p < 0.05) and in the 5.5-7 Hz frequencies during REMS (ANOVA treatment effect: F(1,6) = 8.09, p < 0.05). Food intake was significantly stimulated by 1 µg ghrelin injection (0.74 ± 0.34 g/kg BW on the control day and 7.44 ± 1.26 g/kg BW on the treatment day) (Fig. 7) .
The effects of ghrelin injection into the paraventricular nucleus of the hypothalamus on sleep, EEG and food intake (Figures 5, 6 and 7).
The lowest dose of ghrelin failed to induce any significant change in NREMS, REMS, SWA (Fig. 5 ) or food intake (Fig. 7) when injected into the paraventricular nucleus.
Injection of 0.2 µg ghrelin did not change the time spent awake, in NREMS or REMS and there was no significant effect on EEG SWA (Fig. 5 ). Detailed analysis of EEG power revealed a significant suppression in the 2.5-4.5 Hz frequency range during NREMS (ANOVA, treatment x frequency interaction: F(31,186) = 1.8, p < 0.05) (Fig. 6 ).
Page 13 of 42
14
Food intake was significantly increased from a baseline of 0.82 ± 0.35 g/kg BW to 4.52± 1.14 g/kg BW in response to 0.2 µg ghrelin injection (Fig. 7) .
One µg ghrelin induced a statistically significant increase in time spent awake in the first hour after injection (ANOVA h 1-3, treatment x time interaction: F(2,14) = 3.8; p < 0.05), which was accompanied by a significant decrease in NREMS (ANOVA h 1-3, treatment x time interaction: F(2,14) = 4.5, p < 0.05). EEG SWA did not change in response to 1 µg ghrelin injection (Fig. 5 ). There was a significant increase in EEG power in the 5-5.5 Hz and 7.5 Hz frequencies during wakefulness (ANOVA treatment x time interaction: F(31,186) = 1.9, p < 0.05) (Fig. 6) . Injection of 1 µg ghrelin into the PVN of the rats induced a significant, about 4-fold increase, in food intake (Fig. 7) .
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DISCUSSION
Our findings indicate that microinjections of ghrelin into the LH, MPA and PVN increase wakefulness, suppress NREMS and REMS and affect EEG power in rats. Furthermore, our results are consistent with previous observations reporting multiple hypothalamic sites that are sensitive to the orexigenic action of ghrelin (65) . Together, these findings are consistent with the hypothesis that brain ghrelinergic mechanisms play a role in the regulation of vigilance and feeding.
Icv (52) and systemic (56) injections of ghrelin during the light period suppress sleep in rats. Also, icv injection of ghrelin (19) and des-acyl ghrelin (58) increases spontaneous locomotor activity of rats. The effects of GHSs on sleep in other species are less consistent and dependent on the timing of the administration. In humans, repeated intravenous (i.v.) bolus injections of ghrelin increase slow-wave sleep and decrease REMS (63) . Pulsatile administration of GHRP-6, a GHS-R agonist, increases sleep (12) while, hexarelin, a more potent agonist, suppresses slow-wave sleep and EEG SWA (11).
Single i.v. bolus injection of a third GHS-R agonist, GHRP-2, failed to induce any change on sleep in humans (32) . Systemic injection of ghrelin at dark onset stimulates NREMS in control mice but not in a mutant strain lacking the GHRH-receptor (35) . In the present experiment, microinjection of ghrelin into various sites of the hypothalamus elicited a prompt and robust increase in wakefulness and decrease in sleep.
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The ghrelin-induced increase in wakefulness was most marked when the peptide was injected into the LH. The effects of icv injection of 1 µg ghrelin in our previous study were similar to those seen after the intra-LH injection of 0.2 µg in the present experiments; increasing the icv dose to 5 µg did not result in a further enhancement of the wake-promoting activity (52) . A similar ceiling-like phenomenon is seen after LH microinjection. The lack of a significant effect on REMS after the 1 µg dose may be due to the already short REMS after the control injections; it is likely that ghrelin could not elicit further decreases.
According to the classic view, the posterior/lateral hypothalamus is a "wake-center" since von Economo observed excessive sleepiness in patients with the damage of this region (62) . Electrolytic (51) 57; 67) . Orexinergic mechanisms may contribute to the feeding effects of ghrelin since pretreatment with orexin antibodies attenuates ghrelin-induced eating and the effect of ghrelin was significantly reduced in orexin-deficient mice (57) . We hypothesize that the wake-promoting effects of ghrelin in the LH may also involve the activation of orexinergic mechanisms.
Ghrelin injection into the MPA also increased the amount of wakefulness. The importance of the MPA in the hypothalamic sleep-regulating system is well-documented.
Lesion of the preoptic area suppresses sleep (28), electrical (17) Ghrelin microinjections also markedly affected EEG power. NREMS-associated EEG delta power, particularly the 1.5-4 Hz frequencies, was significantly attenuated in the first hour after 1 µg ghrelin injections into the LH and MPA. Rats had very little NREMS, which is a possible explanation for the attenuated EEG power. The immediate decrease was followed by an increase in EEG SWA after injections into the MPA. Sleep loss, in general, is followed by increases in EEG SWA. It is possible that the delayed increase in EEG SWA is due to the sleep loss in the first hour after ghrelin treatment. The impact of ghrelin on the EEG power extends to wake and REMS. During wake, EEG power in the 6-8 Hz frequencies was increased suggesting that ghrelin induces not only quantitative but also qualitative changes in wakefulness. Similar EEG power increases in the 6.5-7.5 Hz frequencies during REMS after LH microinjections also occurred.
The wake-promoting and food intake-stimulating effects of ghrelin are in the same doserange after both icv (52) and, as the present experiments indicate, hypothalamic injection.
Orexigenic hormones may reduce wakefulness indirectly due to their primary effects on feeding. One possibility is that, since sleep and feeding are mutually exclusive behaviors, an increase in feeding might result in shortened sleep time. The other possibility is that hunger, which is an assumed effect of feeding-stimulatory hormones in rats, may cause discomfort that could also interfere with sleep. Our current finding, however, that intra-PVN injection of 0.2 µg of ghrelin stimulated feeding as strongly as the higher, wake- 20 promoting dose did but did not affect sleep indicates that the assumed hunger and increased eating activity do not necessarily interfere with sleep. Our previous finding that rats with no access to food also respond with increased wakefulness to central injection of ghrelin (52) suggests that the wake-promoting activity of ghrelin is not due to increased feeding behavior. We hypothesize that increased wakefulness and increased feeding are two parallel outputs of a hypothalamic ghrelin-sensitive circuitry that also involves NPY-ergic and orexinergic neurons and possibly NO and CRH. The activation of this mechanism triggers the behavioral sequence characteristic of the first hours of the activity period in rats (dark onset syndrome). In summary, the present study provides further evidence about the role of ghrelin in sleep-wake regulation. The current findings confirm the notion that ghrelin, as a part of a network, integrates homeostatic processes, such as metabolism and sleep. 
